ARCHIVES

In Brief: What’s In A Name? DRCCA Doesn’t Do It; O’Conor Says ICRDB Program Should Consider New Challenges

This article is from The Cancer Letter archive.

Vol. 06 No. 39 | October 3, 1980

Download PDF Visit The Full Archive

Related Articles

Bayer’s HER-2/neu Blood Test Cleared By FDA For Marketing.

December 15, 2000

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

HHS Appeals Board Finds No Misconduct By Popovic

November 12, 1993

Cytopathologists, NCI Recommend New Method For Pap Smear Reports

August 25, 1989

Cancer Prevention: NSABP Publishes P-1 Data, Finds Risk Of Breast Cancer Cut By 49 Percent

September 18, 1998

FDA Approves Mylotarg For First Relapse Of Acute Myeloid Leukemia In Patients 60+.

June 2, 2000